Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

High-Intensity Interval Exercise in Bronchiectasis Patients

3 september 2026 bijgewerkt door: Saglik Bilimleri Universitesi

Investigation of the Effectiveness of High-Intensity Interval Exercise in Bronchiectasis Patients

The aim of our study is to investigate the effect of high-intensity interval exercise (HIIE) on the symptoms of bronchiectasis in patients with the disease. The main questions it aims to answer are:

  1. Does HIIE improve respiratory function in patients with bronchiectasis?
  2. Does HIIE increase functional capacity, peripheral muscle strength, and quality of life in patients with bronchiectasis?
  3. Does HIIE reduce the severity of dyspnea, cough symptoms, and fatigue in patients with bronchiectasis?

The study was designed as a randomized controlled trial. Participants were divided into two groups: intervention and control.

Participants will:

The intervention group will receive HIIE training three days a week along with airway clearance techniques.

The control group would receive only airway clearance techniques. Airway clearance techniques will be provided clinically (three days a week) and at home, according to the needs of the individuals each day of the week.

Studie Overzicht

Toestand

Werving

Conditie

Interventie / Behandeling

Studietype

Ingrijpend

Inschrijving (Geschat)

42

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Locaties

  • Turkije (Türkiye)
    • Keçiören
      • Ankara, Keçiören, Turkije (Türkiye), 06018
        • Werving
        • Gulhane Faculty of Physiotherapy and Rehabilitation
        • Contact:

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

  • Volwassen
  • Oudere volwassene

Accepteert gezonde vrijwilligers

Ja

Beschrijving

Inclusion Criteria:

  1. Being over 18 years of age
  2. Having a clinical and radiological diagnosis of non-cystic fibrosis bronchiectasis
  3. Absence of cognitive impairment (MMT>24)
  4. Being clinically stable (not having experienced any exacerbation in the last 4 weeks)

Exclusion Criteria:

  1. Presence of any disease that may affect compliance with exercise (Unstable angina (within the last month), recent myocardial infarction (heart attack), uncontrolled arrhythmias, severe aortic stenosis, decompensated heart failure, severe pulmonary hypertension, acute respiratory tract infection, severe hypoxemia at rest (<85%), orthopedic or neurological problems that impede walking, severe anemia, acute infections, very high resting blood pressure (systolic >180-200 mmHg, diastolic >100-110 mmHg), psychological issues, etc.)
  2. Smoking
  3. Chronic alcoholism that may affect exercise safety (More than 1 drink per day on average for women, more than 2 drinks per day on average for men (1 standard drink ≈ 10-14 g of alcohol)
  4. Presence of any respiratory tract disease other than bronchiectasis
  5. After incremental shuttle walk test arterial oxygen saturation <80%
  6. Participation in a structured exercise program within the last 6 months

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Actieve vergelijker: Intervention
Patients in this group will perform airway clearance techniques along with high-intensity interval exercise.
Ander: high-intensity interval exercise
The high-intensity interval exercise (HIIE) protocol (4×4 model: 4 minutes at 85-95% maximum heart rate, with 3 minutes of active recovery at 60-70% in between), will be applied 3 days a week for 8 weeks using a treadmill or cycle ergometer, taking into account the participants' physical characteristics and safety requirements.
Ander: Airway clearance tecniques
Among the airway clearance techniques, the active cycle of breathing techniques (ACBT) and manual techniques will be applied. Additionally, the autogenic drainage technique will be taught to patients for them to practice at home. Airway clearance techniques will be demonstrated to the patients practically and they will be asked to perform them daily (3 days a week in the clinic) as needed.
Actieve vergelijker: Control
Patients in this group will only undergo airway clearance techniques.
Ander: Airway clearance tecniques
Among the airway clearance techniques, the active cycle of breathing techniques (ACBT) and manual techniques will be applied. Additionally, the autogenic drainage technique will be taught to patients for them to practice at home. Airway clearance techniques will be demonstrated to the patients practically and they will be asked to perform them daily (3 days a week in the clinic) as needed.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Functional Performance
Tijdsspanne: At the beginning of the study, after 8 weeks of treatment, and at week 4 following the study
Functional performance will be measured using an incremental shuttle walk test.
At the beginning of the study, after 8 weeks of treatment, and at week 4 following the study

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Maximal Inspiratory Pressure (PImax)
Tijdsspanne: At the beginning of the study, after 8 weeks of treatment, and at week 4 following the study.
Inspiratory muscle strength will be assessed by measuring the maximal inspiratory pressure (PImax) using an electronic, portable, intraoral pressure measuring device. PImax represents the maximum negative pressure generated during a forceful inhalation against an occluded airway. Results will be reported in centimeters of water (cmH2O), with higher absolute values indicating greater inspiratory muscle strength.
At the beginning of the study, after 8 weeks of treatment, and at week 4 following the study.
Maximal Expiratory Pressure (PEmax)
Tijdsspanne: At the beginning of the study, after 8 weeks of treatment, and at week 4 following the study.
Expiratory muscle strength will be assessed by measuring the maximal expiratory pressure (PEmax) using an electronic, portable, intraoral pressure measuring device. PEmax represents the maximum positive pressure generated during a forceful exhalation against an occluded airway. Results will be reported in centimeters of water (cmH2O), with higher values indicating greater expiratory muscle strength.
At the beginning of the study, after 8 weeks of treatment, and at week 4 following the study.
Forced Vital Capacity (FVC)
Tijdsspanne: At the beginning of the study, after 8 weeks of treatment, and at week 4 following the study.
Forced Vital Capacity (FVC) is the total volume of air that can be exhaled forcefully and completely after a maximal inspiration. It is measured using spirometry to assess overall lung volume and capacity. The results will be reported as an absolute volume in Liters (L).
At the beginning of the study, after 8 weeks of treatment, and at week 4 following the study.
FEV1 (Forced Expiratory Volume in 1 Second)
Tijdsspanne: At the beginning of the study, after 8 weeks of treatment, and at week 4 following the study.
Forced Expiratory Volume in 1 second (FEV1) is the volume of air forcefully exhaled during the first second after a maximal inspiration, measured using spirometry. Outcomes are reported in absolute volume (Liters) and % to evaluate airway obstruction and overall pulmonary function.
At the beginning of the study, after 8 weeks of treatment, and at week 4 following the study.
FEV1/FVC
Tijdsspanne: At the beginning of the study, after 8 weeks of treatment, and at week 4 following the study
FEV1/FVC(%) will be calculated using the FEV1 and FVC values obtained from the pulmonary function test.
At the beginning of the study, after 8 weeks of treatment, and at week 4 following the study
Fatigue
Tijdsspanne: At the beginning of the study, after 8 weeks of treatment, and at week 4 following the study
To assess the severity of fatigue and its impact on daily life, the Fatigue Severity Scale (FSS), a self-report scale, will be used. The scale consists of 9 items, each scored between 1 (strongly disagree) and 7 (strongly agree). The average score is calculated by dividing the total score by the number of items, with higher scores indicating more severe fatigue. A score of 4 or higher generally indicates severe fatigue.
At the beginning of the study, after 8 weeks of treatment, and at week 4 following the study
Dyspnea Severity
Tijdsspanne: At the beginning of the study, after 8 weeks of treatment, and at week 4 following the study.
Dyspnea severity will be assessed using the Modified Medical Research Council dyspnea scale. The scale classifies dyspnea on a five-point scale from 0 to 4; a score of 0 indicates dyspnea occurring only during strenuous exercise, while a score of 4 describes significant shortness of breath even during the mildest daily activities.
At the beginning of the study, after 8 weeks of treatment, and at week 4 following the study.
The Bronchiectasis Health Questionnaire
Tijdsspanne: At the beginning of the study, after 8 weeks of treatment, and at week 4 following the study
The Bronchiectasis Health Questionnaire (BHQ) will be used to assess disease-specific quality of life. The BHQ is a patient-completed scale consisting of 10 items that evaluates symptom burden, physical function, and the impact of the disease on daily life. Each item is scored between 0 and 7, and the total score ranges from 0 to 70; higher scores indicate better health status and quality of life.
At the beginning of the study, after 8 weeks of treatment, and at week 4 following the study
Cough Questionnaire
Tijdsspanne: At the beginning of the study, after 8 weeks of treatment, and at week 4 following the study.
The Leicester Cough Questionnaire (LCQ) is a disease-specific, patient-completed scale developed to assess the impact of cough on quality of life in individuals with chronic cough. The LLC consists of 19 items and covers three sub-dimensions: physical, psychological, and social. Each item is scored between 1 and 7, and the average of the sub-dimension scores is calculated and summed to obtain a total score ranging from 3 to 21; higher scores indicate better quality of life and less cough-related impact.
At the beginning of the study, after 8 weeks of treatment, and at week 4 following the study.

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Saglik Bilimleri Universitesi

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

27 maart 2026

Primaire voltooiing (Geschat)

31 december 2026

Studie voltooiing (Geschat)

29 mei 2027

Studieregistratiedata

Eerst ingediend

21 april 2026

Eerst ingediend dat voldeed aan de QC-criteria

3 september 2026

Eerst geplaatst (Werkelijk)

4 september 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

4 september 2026

Laatste update ingediend die voldeed aan QC-criteria

3 september 2026

Laatst geverifieerd

1 april 2026

Meer informatie

Termen gerelateerd aan deze studie

Trefwoorden

Aanvullende relevante MeSH-voorwaarden

Andere studie-ID-nummers

  • 2026-085

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Beschrijving IPD-plan

Due to patient confidentiality, data will not be shared.

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren